Cytokine levels of IL-17A were not affected in tocilizumab-treated RA patients in a recent study by Lee et al. [107]; however, higher baseline IL-17A levels were associated with a worse responsiveness to the treatment. Here, IL17A is linked to rheumatoid arthritis.